Yasuhiro Abe

Dr. Yasuhiro Abe

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2011 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
KYKohei Yamashita
Kohei Yamashita
YYYasuo Yoshioka
Yasuo Yoshioka
KHKazuma Higashisaka
Kazuma Higashisaka
KMKazuya Mimura
Kazuya Mimura
YMYuki Morishita
Yuki Morishita
YTYasuo Tsutsumi
Yasuo Tsutsumi

15 January 2011 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
HNHiromi Nabeshi
Hiromi Nabeshi
TYTomoaki Yoshikawa
Tomoaki Yoshikawa
KMKeigo Matsuyama
Keigo Matsuyama
YNYasutaro Nakazato
Yasutaro Nakazato
STSaeko Tochigi
Saeko Tochigi
YTYasuo Tsutsumi
Yasuo Tsutsumi
Background: Clarifying the physicochemical properties of nanomaterials is crucial for hazard assessment and the safe application of these substances. With this in mind, we analyzed the relationship between particle size and the in vitro effect of amorphous nanosilica (nSP). Specifically, we evaluated the relationship between particle size of nSP and the in vitro biological effects using human keratinocyte cells (HaCaT). Results: Our results indicate that exposure to nSP of 70 nm diameter (nSP70) induced an elevated level of reactive oxygen species (ROS), leading to DNA damage. A markedly reduced response was observed using submicron-sized silica particles of 300 and 1000 nm diameter. In addition, cytochalasin D-treatment reduced nSP70-mediated ROS generation and DNA damage, suggesting that endocytosis is involved in nSP70-mediated cellular effects. Conclusions: Thus, particle size affects amorphous silica-induced ROS generation and DNA damage of HaCaT cells. We believe clarification of the endocytosis pathway of nSP will provide useful information for hazard assessment as well as the design of safer forms of nSPs.

1 April 2011 in Biomaterials
Verified
Journal Article
Closed access
HNHiromi Nabeshi
Hiromi Nabeshi
TYTomoaki Yoshikawa
Tomoaki Yoshikawa
KMKeigo Matsuyama
Keigo Matsuyama
YNYasutaro Nakazato
Yasutaro Nakazato
KMKazuhiko Matsuo
Kazuhiko Matsuo
YTYasuo Tsutsumi
Yasuo Tsutsumi

9 June 2016 in Langmuir
Verified
Journal Article
Closed access
YTYuki Takechi-Haraya
Yuki Takechi-Haraya
KSKumiko Sakai-Kato
Kumiko Sakai-Kato
YAYasuhiro Abe
Yasuhiro Abe
TKToru Kawanishi
Toru Kawanishi
HOHaruhiro Okuda
Haruhiro Okuda
YGYukihiro Goda
Yukihiro Goda

20 February 2010 in Inflammation
Verified
Journal Article
Closed access
PDF file
KYKohei Yamashita
Kohei Yamashita
YYYasuo Yoshioka
Yasuo Yoshioka
KHKazuma Higashisaka
Kazuma Higashisaka
YMYuki Morishita
Yuki Morishita
TYTokuyuki Yoshida
Tokuyuki Yoshida
YTYasuo Tsutsumi
Yasuo Tsutsumi

15 December 2010 in Journal of Virology
Verified
Journal Article
Open access
PDF file
HKHiroyuki Kayamuro
Hiroyuki Kayamuro
YYYasuo Yoshioka
Yasuo Yoshioka
YAYasuhiro Abe
Yasuhiro Abe
SAShuhei Arita
Shuhei Arita
KKKazufumi Katayama
Kazufumi Katayama
STShin-Ichi Tsunoda
Shin-Ichi Tsunoda
A safe and potent adjuvant is needed for development of mucosal vaccines against etiological agents, such as influenza virus, that enter the host at mucosal surfaces. Cytokines are potential adjuvants for mucosal vaccines because they can enhance primary and memory immune responses enough to protect against some infectious agents. For this study, we tested 26 interleukin (IL) cytokines as mucosal vaccine adjuvants and compared their abilities to induce antigen (Ag)-specific immune responses against influenza virus. In mice intranasally immunized with recombinant influenza virus hemagglutinin (rHA) plus one of the IL cytokines, IL-1 family cytokines (i.e., IL-1α, IL-1β, IL-18, and IL-33) were found to increase Ag-specific immunoglobulin G (IgG) in plasma and IgA in mucosal secretions compared to those after immunization with rHA alone. In addition, high levels of both Th1- and Th2-type cytokines were observed in mice immunized with rHA plus an IL-1 family cytokine. Furthermore, mice intranasally immunized with rHA plus an IL-1 family cytokine had significant protection against a lethal influenza virus infection. Interestingly, the adjuvant effects of IL-18 and IL-33 were significantly decreased in mast cell-deficientW/Wvmice, indicating that mast cells have an important role in induction of Ag-specific mucosal immune responses induced by IL-1 family cytokines. In summary, our results demonstrate that IL-1 family cytokines are potential mucosal vaccine adjuvants and can induce Ag-specific immune responses for protection against pathogens like influenza virus.